Clinical Relevance of the Anti-inflammatory Effects of Roflumilast on Human Bronchus: Potentiation by a Long-Acting Beta-2-Agonist

Background: Roflumilast is an option for treating patients with severe COPD and frequent exacerbations despite optimal therapy with inhaled drugs. The present study focused on whether the phosphodiesterase (PDE) 4 inhibitor roflumilast and its active metabolite roflumilast N-oxide affect the release...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Hélène Salvator, Amparo Buenestado, Marion Brollo, Emmanuel Naline, Tatiana Victoni, Elisabeth Longchamp, Hermann Tenor, Stanislas Grassin-Delyle, Philippe Devillier
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2020-12-01
Edice:	Frontiers in Pharmacology
Témata:	roflumilast beta-2-adrenoceptor agonist human bronchus cytokine lipopolysaccharide
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fphar.2020.598702/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!